Your browser doesn't support javascript.
COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series.
Walmsley, Sharon L; Szadkowski, Leah; Wouters, Bradly; Clarke, Rosemarie; Colwill, Karen; Rochon, Paula; Brudno, Michael; Ravindran, Rizanni; Raboud, Janet; McGeer, Allison; Oza, Amit; Graham, Christopher; Silva, Amanda; Manase, Dorin; Maksymowsky, Peter; Parente, Laura; Dayam, Roaya Monica; Simpson, Jacqueline; Pasculescu, Adrian; Gingras, Anne-Claude.
  • Walmsley SL; Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Szadkowski L; Toronto General Hospital Research Institute, University of Toronto, Toronto, ON, Canada.
  • Wouters B; University of Toronto, Toronto, ON, Canada.
  • Clarke R; Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Colwill K; University of Toronto, Toronto, ON, Canada.
  • Rochon P; Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Brudno M; University of Toronto, Toronto, ON, Canada.
  • Ravindran R; Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Raboud J; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
  • McGeer A; University of Toronto, Toronto, ON, Canada.
  • Oza A; Women's College Hospital Research Institute, University of Toronto, Toronto, ON, Canada.
  • Graham C; University of Toronto, Toronto, ON, Canada.
  • Silva A; Department of Computer Science, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Manase D; University of Toronto, Toronto, ON, Canada.
  • Maksymowsky P; Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Parente L; University of Toronto, Toronto, ON, Canada.
  • Dayam RM; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Simpson J; University of Toronto, Toronto, ON, Canada.
  • Pasculescu A; Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
  • Gingras AC; University of Toronto, Toronto, ON, Canada.
iScience ; 26(4): 106506, 2023 Apr 21.
Article in English | MEDLINE | ID: covidwho-2305420
ABSTRACT
We report a decentralized prospective cohort study of self-reported adverse events and antibody responses to COVID vaccines derived from dried blood spots. Data are presented for 911 older (aged >70 years) and 375 younger (30-50 years) recruits to 48 weeks after the primary vaccine series. After a single vaccine, 83% younger and 45% older participants had overall seropositivity (p < 0.0001) increasing to 100/98% with the second dose, respectively (p = 0.084). A cancer diagnosis (p = 0.009), no mRNA-1273 vaccine doses (p <0 .0001), and older age (p <0 .0001) predicted lower responses. Antibody levels declined in both cohorts at 12 and 24 weeks increasing with booster doses. At 48 weeks, for participants with 3 vaccine doses, the median antibody levels were higher in the older cohort (p = 0.04) with any dose of mRNA-1273 (p <0 .0001) and with COVID infection (p <0 .001). The vaccines were well tolerated. Breakthrough COVID infections were uncommon (16% older cohort, 29% younger cohort; p < 0.0001) and mild.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Language: English Journal: IScience Year: 2023 Document Type: Article Affiliation country: J.isci.2023.106506

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Language: English Journal: IScience Year: 2023 Document Type: Article Affiliation country: J.isci.2023.106506